You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of GenomeBuild as a Universal Method to Synthesize Genomes
SBC: Proteovista LLC Topic: 172Project Summary Development of GenomeBuild as a Universal Method to Synthesize GenomesOpportunity Number: RFA-HG-20-016PIs: Christopher L. Warren and Mary S. Ozers Synthetic biology encompasses the ability to de novo synthesize and assemble large oligonucleotides into genomes of whole organisms, with a broad range of applications in medicine, therapeutics, environmental sciences, and human genomic ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Modeling Professional Attitudes and Teaching Humanistic Communication to Remedy Implicit Bias and Promote Cultural Humility in Healthcare (MPathic-IBCH).
SBC: MEDICAL CYBERWORLDS, INC. Topic: NIMHDImplicit bias (IB) negatively impacts the medical care and health outcomes of Black patients. Physician IB compromises the quality of patient-physician communication, eroding trust and confidence, impairing treatment decisions and adherence, and causing patient harm. Studies show that non-Black physicians, on average, have moderate levels of IB toward Black patients. Since most Black patients see ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A Disease-Modifying Protein Therapeutic for the Treatment of COPD
SBC: VERRA THERAPEUTICS LLC Topic: NHLBIPROJECT SUMMARY Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide at 3.23 million (2019), while nearly 400 million suffer its effects. COPD is a heterogeneous, multi-phenotypic disease with lung damage derived from smoking, vaping, cooking, forest fires, pollution, chemical exposure, and numerous occupational hazards (e.g., 1st responders, military, agricul ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Multi-Omics And Synbio Enabled Discovery Of Antifungal Fernene Triterpenes
SBC: Varigen Biosciences Corporation Topic: NIAIDProject Summary. A new functional metabologenomics approach is proposed for the development of a second generation of fernene-based antifungal terpenes. Our team led by Mead (Varigen), Keller (University of Wisconsin) and Kelleher (Northwestern University) explore the diversity of this unique family of triterpenes using a fusion of technologies that unites genomics with metabolomic understanding o ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Carbon Nanotube-Mediated Gene Transfer into Human T-cells for CAR-T HIV Therapy
SBC: Advanced Gene Transfer Company, Inc. Topic: 105ABSTRACT The HIV pandemic has caused an estimated 33 million deaths to date. In the U.S. alone, 1.2 million people currently live with HIV and 34,800 new cases were diagnosed in 2019. This adds up to an estimated $16.4 billion for a lifetime of HIV treatment for patients in the U.S. HIV infects immune cells which express the CD4 and CXCR4/CCR5 co-receptors including helper T-cells. Even after a pa ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Molecular Diagnostic to Identify Dangerous Intracranial Aneurysms
SBC: NEUROVASCULAR DIAGNOSTICS, INC. Topic: 103Project SummaryIntracranial aneurysm (IA) rupture is the primary cause of non-traumatic subarachnoid hemorrhage, a catastrophic event that carries high rates of mortality (rt50%) and permanent disability (rt50% among survivors). When an unruptured IA is discovered, clinicians face the difficult decision of whether or not it should be treated. Since rupture rates are low (risk of rupture ~ 0.5-1% p ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
SBC: DNASTAR, INC. Topic: NIAIDTherapeutic monoclonal antibodies bind to specific regions of proteins called epitopes, which elicit cellular responses that treat or cure disease. Discovering therapeutic antibodies traditionally requires costly and labor- intensive, laboratory-based screening experiments. Computational approaches that select antibodies with the most desirable pharmaceutical properties are thus poised to improve ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities
SBC: EPIVAX, INC. Topic: NIAIDABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Non-Clinical Pharmacology of CX-01
SBC: Ceramedix Holding, LLC Topic: NIAIDDevelopment of radiation medical countermeasures (MCM) has become a national security priority owing to such threats as radiological dispersal devices (i.e., “dirty bomb”) and nuclear accidents, which may be caused by extreme weather (such as occurred in Fukushima, Japan in 2011). Radiation exposure can be potentially lethal via the hematopoietic-acute radiation syndrome (H-ARS) and the gastro ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Chimeric antigen receptor-modified iNKT cell therapy for CD7+ malignancies
SBC: Akeso Therapeutics Inc Topic: 102PROJECT SUMMARY/ABSTRACTThe major hurdle in developing chimeric antigen receptor (CAR)-T therapy for T-cell malignancies is CAR-T cell fratricide by self-killing, which leads to insufficient numbers of CAR-T cells for infusion. CRISPR- mediated genomic editing provides an alternative approach to enabling expansion of CAR transduced T cells from allogeneic healthy donors. However, the safety and cl ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health